Protocol T comparison of anti-VEGFs gives clinicians guidance for treating DME

Eagerly awaited findings of the DRCR.net Protocol T study did not disappoint, delivering “exciting” results for retina specialists looking for an answer to the question of which anti-VEGF to use in cases of center-involved diabetic macular edema.One-year results of the head-to-head comparison of Eylea (aflibercept, Regeneron), Avastin (bevacizumab, Genentech) and Lucentis (ranibizumab, Genentech) showed all three drugs similarly improved vision, on average, in patients with baseline visual acuity of 20/40 to 20/32, but for patients with baseline visual acuity of 20/50 or worse, statistically significantly greater mean improvement in visual acuity was achieved using aflibercept.